Skip to main content
Top
Published in: Heart and Vessels 2/2012

01-03-2012 | Original Article

Urocortin-induced cardiomyocytes hypertrophy is associated with regulation of the GSK-3β pathway

Authors: Damien Gruson, Audrey Ginion, Noémie Decroly, Pascale Lause, Jean-Louis Vanoverschelde, Jean-Marie Ketelslegers, Luc Bertrand, Jean-Paul Thissen

Published in: Heart and Vessels | Issue 2/2012

Login to get access

Abstract

Urocortin-1 (UCN), a member of the corticotropin-releasing factor, is a cardioprotective peptide, and is also involved in cardiac hypertrophy. The involvement of GSK-3β, a pivotal kinase in cardiac hypertrophy, in response to UCN is not yet documented. Cardiomyocytes from adult rats were stimulated for 48 h with UCN. Cell size, protein, and DNA contents were determined. Phosphorylated and total forms GSK-3β and the total amount of β-catenin were quantified by Western immunoblots. The effects of astressin, a UCN competitive receptor antagonist, were also evaluated. UCN increased cell size and the protein-to-DNA ratio, in accordance with a hypertrophic response. This effect was associated with increased phosphorylation of GSK-3β and marked accumulation of β-catenin, a downstream element to GSK-3β. All these effects were prevented by astressin and LY294002, an inhibitor of the phosphatidyl-inositol-3-kinase. UCN-induced cardiomyocytes hypertrophy is associated with regulation of GSK-3β, a pivotal kinase involved in cardiac hypertrophy, in a PI3K-dependent manner. Furthermore, the pharmacological blockade of UCN receptors was able to prevent UCN-induced hypertrophy, which leads to inhibition of the Akt/GSK-3β pathway.
Literature
1.
go back to reference Dautzenberg FM, Hauger RL (2002) The CRF peptide family and their receptors: yet more partners discovered. Trends Pharmacol Sci 23:71–77PubMedCrossRef Dautzenberg FM, Hauger RL (2002) The CRF peptide family and their receptors: yet more partners discovered. Trends Pharmacol Sci 23:71–77PubMedCrossRef
2.
go back to reference Burnett JC Jr (2005) Urocortin: advancing the neurohumoral hypothesis of heart failure. Circulation 112:3544–3546PubMedCrossRef Burnett JC Jr (2005) Urocortin: advancing the neurohumoral hypothesis of heart failure. Circulation 112:3544–3546PubMedCrossRef
3.
go back to reference Charles CJ, Rademaker MT, Richards AM (2004) Urocortins: putative role in cardiovascular disease. Curr Med Chem Cardiovasc Hematol Agents 2:43–47PubMedCrossRef Charles CJ, Rademaker MT, Richards AM (2004) Urocortins: putative role in cardiovascular disease. Curr Med Chem Cardiovasc Hematol Agents 2:43–47PubMedCrossRef
4.
go back to reference Kimura Y, Takahashi K, Totsune K, Muramatsu Y, Kaneko C, Darnel AD, Suzuki T, Ebina M, Nukiwa T, Sasano H (2002) Expression of urocortin and corticotropin-releasing factor receptor subtypes in the human heart. J Clin Endocrinol Metab 87:340–346PubMedCrossRef Kimura Y, Takahashi K, Totsune K, Muramatsu Y, Kaneko C, Darnel AD, Suzuki T, Ebina M, Nukiwa T, Sasano H (2002) Expression of urocortin and corticotropin-releasing factor receptor subtypes in the human heart. J Clin Endocrinol Metab 87:340–346PubMedCrossRef
5.
go back to reference Nishikimi T, Miyata A, Horio T, Yoshihara F, Nagaya N, Takishita S, Yutani C, Matsuo H, Matsuoka H, Kangawa K (2000) Urocortin, a member of the corticotropin-releasing factor family, in normal and diseased heart. Am J Physiol Heart Circ Physiol 279:H3031–H3039PubMed Nishikimi T, Miyata A, Horio T, Yoshihara F, Nagaya N, Takishita S, Yutani C, Matsuo H, Matsuoka H, Kangawa K (2000) Urocortin, a member of the corticotropin-releasing factor family, in normal and diseased heart. Am J Physiol Heart Circ Physiol 279:H3031–H3039PubMed
6.
go back to reference Wright SP, Doughty RN, Frampton CM, Gamble GD, Yandle TG, Richards AM (2009) Plasma urocortin 1 in human heart failure. Circ Heart Fail 2:465–471PubMedCrossRef Wright SP, Doughty RN, Frampton CM, Gamble GD, Yandle TG, Richards AM (2009) Plasma urocortin 1 in human heart failure. Circ Heart Fail 2:465–471PubMedCrossRef
7.
go back to reference Ng LL, Loke IW, O’Brien RJ, Squire IB, Davies JE (2004) Plasma urocortin in human systolic heart failure. Clin Sci 106:383–388PubMedCrossRef Ng LL, Loke IW, O’Brien RJ, Squire IB, Davies JE (2004) Plasma urocortin in human systolic heart failure. Clin Sci 106:383–388PubMedCrossRef
8.
go back to reference Gruson D, Ahn SA, Ketelslegers JM, Rousseau MF (2010) Circulating levels of stress associated peptide urocortin in heart failure patients. Peptides 31:354–356PubMedCrossRef Gruson D, Ahn SA, Ketelslegers JM, Rousseau MF (2010) Circulating levels of stress associated peptide urocortin in heart failure patients. Peptides 31:354–356PubMedCrossRef
9.
go back to reference Wiley KE, Davenport AP (2004) CRF2 receptors are highly expressed in the human cardiovascular system and their cognate ligands urocortins 2 and 3 are potent vasodilators. Br J Pharmacol 143:508–514PubMedCrossRef Wiley KE, Davenport AP (2004) CRF2 receptors are highly expressed in the human cardiovascular system and their cognate ligands urocortins 2 and 3 are potent vasodilators. Br J Pharmacol 143:508–514PubMedCrossRef
10.
go back to reference Shioi T, Kang PM, Douglas PS, Hampe J, Yballe CM, Lawitts J, Cantley LC, Izumo S (2000) The conserved phosphoinositide 3-kinase pathway determines heart size in mice. EMBO J 19:2537–2548PubMedCrossRef Shioi T, Kang PM, Douglas PS, Hampe J, Yballe CM, Lawitts J, Cantley LC, Izumo S (2000) The conserved phosphoinositide 3-kinase pathway determines heart size in mice. EMBO J 19:2537–2548PubMedCrossRef
11.
go back to reference Dorn GW, Force T (2005) Protein kinase cascades in the regulation of cardiac hypertrophy. J Clin Invest 115:527–537PubMed Dorn GW, Force T (2005) Protein kinase cascades in the regulation of cardiac hypertrophy. J Clin Invest 115:527–537PubMed
12.
go back to reference Chanalaris A, Lawrence KM, Townsend PA, Davidson S, Jamshidi Y, Stephanou A, Knight RD, Hsu SY, Hsueh AJ, Latchman DS (2005) Hypertrophic effects of urocortin homologous peptides are mediated via activation of the Akt pathway. Biochem Biophys Res Commun 328:442–448PubMedCrossRef Chanalaris A, Lawrence KM, Townsend PA, Davidson S, Jamshidi Y, Stephanou A, Knight RD, Hsu SY, Hsueh AJ, Latchman DS (2005) Hypertrophic effects of urocortin homologous peptides are mediated via activation of the Akt pathway. Biochem Biophys Res Commun 328:442–448PubMedCrossRef
13.
go back to reference Kerkela R, Woulfe K, Force T (2007) Glycogen synthase kinase-3beta—actively inhibiting hypertrophy. Trends Cardiovasc Med 17:91–96PubMedCrossRef Kerkela R, Woulfe K, Force T (2007) Glycogen synthase kinase-3beta—actively inhibiting hypertrophy. Trends Cardiovasc Med 17:91–96PubMedCrossRef
14.
go back to reference Hardt SE, Sadoshima J (2002) Glycogen synthase kinase-3beta: a novel regulator of cardiac hypertrophy and development. Circ Res 90:1055–1063PubMedCrossRef Hardt SE, Sadoshima J (2002) Glycogen synthase kinase-3beta: a novel regulator of cardiac hypertrophy and development. Circ Res 90:1055–1063PubMedCrossRef
15.
go back to reference Sugden PH, Fuller SJ, Weiss SC, Clerk A (2008) Glycogen synthase kinase 3 (GSK3) in the heart: a point of integration in hypertrophic signalling and a therapeutic target? A critical analysis. Br J Pharmacol 153(Suppl 1):S137–S153PubMed Sugden PH, Fuller SJ, Weiss SC, Clerk A (2008) Glycogen synthase kinase 3 (GSK3) in the heart: a point of integration in hypertrophic signalling and a therapeutic target? A critical analysis. Br J Pharmacol 153(Suppl 1):S137–S153PubMed
16.
go back to reference Kim Y, Park MK, Chung S (2010) Protective effect of urocortin on 1-methyl-4-phenylpyridinium-induced dopaminergic neuronal death. Mol Cells 30(5):427–433 Kim Y, Park MK, Chung S (2010) Protective effect of urocortin on 1-methyl-4-phenylpyridinium-induced dopaminergic neuronal death. Mol Cells 30(5):427–433
17.
go back to reference Wang MJ, Lin SZ, Kuo JS, Huang HY, Tzeng SF, Liao CH, Chen DC, Chen WF (2007) Urocortin modulates inflammatory response and neurotoxicity induced by microglial activation. J Immunol 179:6204–6214PubMed Wang MJ, Lin SZ, Kuo JS, Huang HY, Tzeng SF, Liao CH, Chen DC, Chen WF (2007) Urocortin modulates inflammatory response and neurotoxicity induced by microglial activation. J Immunol 179:6204–6214PubMed
18.
go back to reference Huang HY, Lin SZ, Chen WF, Li KW, Kuo JS, Wang MJ (2009) Urocortin modulates dopaminergic neuronal survival via inhibition of glycogen synthase kinase-3beta and histone deacetylase. Neurobiol Aging [Epub ahead of print] Huang HY, Lin SZ, Chen WF, Li KW, Kuo JS, Wang MJ (2009) Urocortin modulates dopaminergic neuronal survival via inhibition of glycogen synthase kinase-3beta and histone deacetylase. Neurobiol Aging [Epub ahead of print]
19.
go back to reference Gruson D, Ginion A, Decroly N, Lause P, Vanoverschelde JL, Ketelslegers JM, Bertrand L, Thissen JP (2010) Urotensin II induction of adult cardiomyocytes hypertrophy involves the Akt/GSK-3beta signaling pathway. Peptides 31:1326–1333PubMedCrossRef Gruson D, Ginion A, Decroly N, Lause P, Vanoverschelde JL, Ketelslegers JM, Bertrand L, Thissen JP (2010) Urotensin II induction of adult cardiomyocytes hypertrophy involves the Akt/GSK-3beta signaling pathway. Peptides 31:1326–1333PubMedCrossRef
20.
go back to reference Ikeda K, Tojo K, Otsubo C, Udagawa T, Hosoya T, Tajima N, Nakao K, Kawamura M (2005) Effects of urocortin II on neonatal rat cardiac myocytes and non-myocytes. Peptides 26:2473–2481PubMedCrossRef Ikeda K, Tojo K, Otsubo C, Udagawa T, Hosoya T, Tajima N, Nakao K, Kawamura M (2005) Effects of urocortin II on neonatal rat cardiac myocytes and non-myocytes. Peptides 26:2473–2481PubMedCrossRef
21.
go back to reference Brar BK, Stephanou A, Knight R, Latchman DS (2002) Activation of protein kinase B/Akt by urocortin is essential for its ability to protect cardiac cells against hypoxia/reoxygenation-induced cell death. J Mol Cell Cardiol 34:483–492PubMedCrossRef Brar BK, Stephanou A, Knight R, Latchman DS (2002) Activation of protein kinase B/Akt by urocortin is essential for its ability to protect cardiac cells against hypoxia/reoxygenation-induced cell death. J Mol Cell Cardiol 34:483–492PubMedCrossRef
22.
go back to reference Ikeda K, Tojo K, Sato S, Ebisawa T, Tokudome G, Hosoya T, Harada M, Nakagawa O, Nakao K (1998) Urocortin, a newly identified corticotropin-releasing factor-related mammalian peptide, stimulates atrial natriuretic peptide and brain natriuretic peptide secretions from neonatal rat cardiomyocytes. Biochem Biophys Res Commun 250:298–304PubMedCrossRef Ikeda K, Tojo K, Sato S, Ebisawa T, Tokudome G, Hosoya T, Harada M, Nakagawa O, Nakao K (1998) Urocortin, a newly identified corticotropin-releasing factor-related mammalian peptide, stimulates atrial natriuretic peptide and brain natriuretic peptide secretions from neonatal rat cardiomyocytes. Biochem Biophys Res Commun 250:298–304PubMedCrossRef
23.
go back to reference Antos CL, McKinsey TA, Frey N, Kutschke W, McAnally J, Shelton JM, Richardson JA, Hill JA, Olson EN (2002) Activated glycogen synthase-3 beta suppresses cardiac hypertrophy in vivo. Proc Natl Acad Sci USA 99:907–912PubMedCrossRef Antos CL, McKinsey TA, Frey N, Kutschke W, McAnally J, Shelton JM, Richardson JA, Hill JA, Olson EN (2002) Activated glycogen synthase-3 beta suppresses cardiac hypertrophy in vivo. Proc Natl Acad Sci USA 99:907–912PubMedCrossRef
24.
go back to reference Kerkela R, Kockeritz L, Macaulay K, Zhou J, Doble BW, Beahm C, Greytak S, Woulfe K, Trivedi CM, Woodgett JR, Epstein JA, Force T, Huggins GS (2008) Deletion of GSK-3beta in mice leads to hypertrophic cardiomyopathy secondary to cardiomyoblast hyperproliferation. J Clin Invest 118:3609–3618PubMedCrossRef Kerkela R, Kockeritz L, Macaulay K, Zhou J, Doble BW, Beahm C, Greytak S, Woulfe K, Trivedi CM, Woodgett JR, Epstein JA, Force T, Huggins GS (2008) Deletion of GSK-3beta in mice leads to hypertrophic cardiomyopathy secondary to cardiomyoblast hyperproliferation. J Clin Invest 118:3609–3618PubMedCrossRef
25.
go back to reference Force T, Woodgett JR (2009) Unique and overlapping functions of GSK-3 isoforms in cell differentiation and proliferation and cardiovascular development. J Biol Chem 284:9643–9647PubMedCrossRef Force T, Woodgett JR (2009) Unique and overlapping functions of GSK-3 isoforms in cell differentiation and proliferation and cardiovascular development. J Biol Chem 284:9643–9647PubMedCrossRef
26.
go back to reference Otsuka K, Terasaki F, Shimomura H, Tsukada B, Horii T, Isomura T, Suma H, Shibayama Y, Kitaura Y (2010) Enhanced expression of the ubiquitin–proteasome system in the myocardium from patients with dilated cardiomyopathy referred for left ventriculoplasty: an immunohistochemical study with special reference to oxidative stress. Heart Vessels 25:474–484PubMedCrossRef Otsuka K, Terasaki F, Shimomura H, Tsukada B, Horii T, Isomura T, Suma H, Shibayama Y, Kitaura Y (2010) Enhanced expression of the ubiquitin–proteasome system in the myocardium from patients with dilated cardiomyopathy referred for left ventriculoplasty: an immunohistochemical study with special reference to oxidative stress. Heart Vessels 25:474–484PubMedCrossRef
27.
go back to reference Haq S, Michael A, Andreucci M, Bhattacharya K, Dotto P, Walters B, Woodgett J, Kilter H, Force T (2003) Stabilization of beta-catenin by a Wnt-independent mechanism regulates cardiomyocyte growth. Proc Natl Acad Sci USA 100:4610–4615PubMedCrossRef Haq S, Michael A, Andreucci M, Bhattacharya K, Dotto P, Walters B, Woodgett J, Kilter H, Force T (2003) Stabilization of beta-catenin by a Wnt-independent mechanism regulates cardiomyocyte growth. Proc Natl Acad Sci USA 100:4610–4615PubMedCrossRef
28.
go back to reference Railson JE, Liao Z, Brar BK, Buddle JC, Pennica D, Stephanou A, Latchman DS (2002) Cardiotrophin-1 and urocortin cause protection by the same pathway and hypertrophy via distinct pathways in cardiac myocytes. Cytokine 17:243–253PubMedCrossRef Railson JE, Liao Z, Brar BK, Buddle JC, Pennica D, Stephanou A, Latchman DS (2002) Cardiotrophin-1 and urocortin cause protection by the same pathway and hypertrophy via distinct pathways in cardiac myocytes. Cytokine 17:243–253PubMedCrossRef
29.
go back to reference Hiraoka E, Kawashima S, Takahashi T, Rikitake Y, Hirase T, Yokoyama M (2003) PI 3-kinase-Akt-p70 S6 kinase in hypertrophic responses to leukemia inhibitory factor in cardiac myocytes. Kobe J Med Sci 49:25–37PubMed Hiraoka E, Kawashima S, Takahashi T, Rikitake Y, Hirase T, Yokoyama M (2003) PI 3-kinase-Akt-p70 S6 kinase in hypertrophic responses to leukemia inhibitory factor in cardiac myocytes. Kobe J Med Sci 49:25–37PubMed
30.
go back to reference O’toole A, Moule SK, Lockyer PJ, Halestrap AP (2001) Tumour necrosis factor-alpha activation of protein kinase B in WEHI-164 cells is accompanied by increased phosphorylation of Ser473, but not Thr308. Biochem J 359:119–127PubMedCrossRef O’toole A, Moule SK, Lockyer PJ, Halestrap AP (2001) Tumour necrosis factor-alpha activation of protein kinase B in WEHI-164 cells is accompanied by increased phosphorylation of Ser473, but not Thr308. Biochem J 359:119–127PubMedCrossRef
31.
go back to reference Lu C, Schwartzbauer G, Sperling MA, Devaskar SU, Thamotharan S, Robbins PD, McTiernan CF, Liu JL, Jiang J, Frank SJ, Menon RK (2001) Demonstration of direct effects of growth hormone on neonatal cardiomyocytes. J Biol Chem 276:22892–22900PubMedCrossRef Lu C, Schwartzbauer G, Sperling MA, Devaskar SU, Thamotharan S, Robbins PD, McTiernan CF, Liu JL, Jiang J, Frank SJ, Menon RK (2001) Demonstration of direct effects of growth hormone on neonatal cardiomyocytes. J Biol Chem 276:22892–22900PubMedCrossRef
32.
go back to reference Kenessey A, Ojamaa K (2006) Thyroid hormone stimulates protein synthesis in the cardiomyocyte by activating the Akt-mTOR and p70S6 K pathways. J Biol Chem 281:20666–20672PubMedCrossRef Kenessey A, Ojamaa K (2006) Thyroid hormone stimulates protein synthesis in the cardiomyocyte by activating the Akt-mTOR and p70S6 K pathways. J Biol Chem 281:20666–20672PubMedCrossRef
33.
go back to reference He JG, Chen SL, Huang YY, Dong YG, Ma H (2010) The nonpeptide AVE0991 attenuates myocardial hypertrophy as induced by angiotensin II through downregulation of transforming growth factor-beta1/Smad2 expression. Heart Vessels 25:438–443PubMedCrossRef He JG, Chen SL, Huang YY, Dong YG, Ma H (2010) The nonpeptide AVE0991 attenuates myocardial hypertrophy as induced by angiotensin II through downregulation of transforming growth factor-beta1/Smad2 expression. Heart Vessels 25:438–443PubMedCrossRef
34.
go back to reference Omae K, Ogawa T, Yoshikawa M, Nitta K (2010) The use of H1-receptor antagonists and left ventricular remodeling in patients on chronic hemodialysis. Heart Vessels 25:163–169PubMedCrossRef Omae K, Ogawa T, Yoshikawa M, Nitta K (2010) The use of H1-receptor antagonists and left ventricular remodeling in patients on chronic hemodialysis. Heart Vessels 25:163–169PubMedCrossRef
35.
go back to reference Hernandez F, Nido JD, Avila J, Villanueva N (2009) GSK3 inhibitors and disease. Mini Rev Med Chem 9:1024–1029PubMedCrossRef Hernandez F, Nido JD, Avila J, Villanueva N (2009) GSK3 inhibitors and disease. Mini Rev Med Chem 9:1024–1029PubMedCrossRef
36.
go back to reference Cohen P, Goedert M (2004) GSK3 inhibitors development and therapeutic potential. Nat Rev Drug Discov 3:479–487PubMedCrossRef Cohen P, Goedert M (2004) GSK3 inhibitors development and therapeutic potential. Nat Rev Drug Discov 3:479–487PubMedCrossRef
Metadata
Title
Urocortin-induced cardiomyocytes hypertrophy is associated with regulation of the GSK-3β pathway
Authors
Damien Gruson
Audrey Ginion
Noémie Decroly
Pascale Lause
Jean-Louis Vanoverschelde
Jean-Marie Ketelslegers
Luc Bertrand
Jean-Paul Thissen
Publication date
01-03-2012
Publisher
Springer Japan
Published in
Heart and Vessels / Issue 2/2012
Print ISSN: 0910-8327
Electronic ISSN: 1615-2573
DOI
https://doi.org/10.1007/s00380-011-0141-5

Other articles of this Issue 2/2012

Heart and Vessels 2/2012 Go to the issue